Granulomatosis with Polyangiitis News and Research

RSS
Researchers identify new therapeutic for patients with a rare autoimmune disease EGPA

Researchers identify new therapeutic for patients with a rare autoimmune disease EGPA

Three new guidelines released for treatment and management of systemic vasculitis

Three new guidelines released for treatment and management of systemic vasculitis

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease released

The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease released

Researchers reveal promising biomarker for vascular disease relapse

Researchers reveal promising biomarker for vascular disease relapse

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA-approved drug improves clinical outcomes among patients with rare immunologic disease

FDA-approved drug improves clinical outcomes among patients with rare immunologic disease

Two new studies on eosinophilic granulomatosis with polyangiitis selected by Vasculitis Foundation

Two new studies on eosinophilic granulomatosis with polyangiitis selected by Vasculitis Foundation

New study launched to find impact of vasculitis on employment, income

New study launched to find impact of vasculitis on employment, income

NICE approves MabThera for treating severe forms of GPA and MPA

NICE approves MabThera for treating severe forms of GPA and MPA

Vasculitis damage swift, accumulating

Vasculitis damage swift, accumulating

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Powerful new option for treating vasculitis

Powerful new option for treating vasculitis

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

ANCA-associated vasculitis not a single clinical entity

ANCA-associated vasculitis not a single clinical entity

HHS scientists to share recent rheumatology findings at 75th ACR annual meeting

HHS scientists to share recent rheumatology findings at 75th ACR annual meeting

Psychological stress can trigger flares of vasculitis

Psychological stress can trigger flares of vasculitis

Roche Canada grants Vasculitis and Scleroderma Fellowship

Roche Canada grants Vasculitis and Scleroderma Fellowship

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec first quarter revenues increase 9% to $1.2 billion

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.